Page last updated: 2024-10-26

famotidine and Carcinoma, Hepatocellular

famotidine has been researched along with Carcinoma, Hepatocellular in 2 studies

Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.

Research Excerpts

ExcerptRelevanceReference
"Unresectable hepatocellular carcinoma (HCC) has a poor prognosis and little sensitivity to anticancer agents."1.28[Intraarterial combination immunotherapy in hepatocellular carcinoma]. ( Hazama, S; Iizuka, N; Murakami, T; Oka, M; Shimizu, R; Suzuki, T; Yano, K; Yoshino, S, 1990)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Oka, M2
Hazama, S2
Yoshino, S2
Shimoda, K1
Suzuki, M1
Shimizu, R2
Yano, K2
Nishida, M1
Suzuki, T2
Iizuka, N1
Murakami, T1

Trials

1 trial available for famotidine and Carcinoma, Hepatocellular

ArticleYear
Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma: preliminary results.
    Cancer immunology, immunotherapy : CII, 1994, Volume: 38, Issue:3

    Topics: Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Famotidin

1994

Other Studies

1 other study available for famotidine and Carcinoma, Hepatocellular

ArticleYear
[Intraarterial combination immunotherapy in hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Hepatocellular; Cycl

1990